Arrowhead Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARWR | IONS | ALNY | BBIO | ADRX | MAZE | |
|---|---|---|---|---|---|---|
| Market cap | 8.58B | 7.26B | 30.38B | 12.85B | 1.92B | 1.54B |
| P/E (TTM) | — | — | 38.3 | — | — | — |
| Forward P/E | -12.3 | -39.3 | 18.3 | 2,275.1 | — | -8.6 |
| Price/book | 18.4 | 16.4 | 22.4 | -5.1 | -0.8 | 3.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +68.88% | −35.85% | −51.17% | +16.37% | −7.13% | −5.11% |
| Today | −3.22% | −3.56% | −2.43% | +0.61% | +1.07% | +2.18% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARWR news ›Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/dL…
Arrowhead’s Plozasiran Trial Completion Signals a Pivotal Moment for ARWR Investors
Arrowhead Pharmaceuticals, Inc. (ARWR) announced an update on their ongoing clinical study. Arrowhead Pharmaceuticals, Inc. has completed a Phase 3 study called “Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and…
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia - FDA STAR pilot program aims to shorten the time from complete supplement submission to…
Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals plozasiran met its primary and secondary endpoints in two phase 3 studies as a potential treatment for adults with severe hypertriglyceridemia, the company said... Biotechnology & Medical Research Arrowhead…
Arrowhead Pharmaceuticals, Inc. : Insider Transactions
Follow insider transactions on Arrowhead Pharmaceuticals, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Arrowhead Pharmaceuticals, Inc. Biotechnology & Medical…
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
Presentation Operator MessageOperator Good morning, everyone, and welcome to the Arrowhead Pharmaceuticals Investor Webcast. [Operator Instructions] As a reminder, this call is being recorded, and Transcript : Arrowhead Pharmaceuticals,…
Arrowhead Pharmaceuticals, Inc.: Latest Headlines - Nasdaq Stock Exchange
Find the latest highlights on Arrowhead Pharmaceuticals, Inc. at the Nasdaq stock exchange. Highlights Arrowhead Pharmaceuticals, Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
All Transcripts on Arrowhead Pharmaceuticals, Inc. (ARWR)
Find all the latest transcripts on Arrowhead Pharmaceuticals, Inc. Transcripts Arrowhead Pharmaceuticals, Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
Arrowhead Pharmaceuticals, Inc.: Official Announcements - Stock Market News
Find the latest press releases and official documents published by Arrowhead Pharmaceuticals, Inc. on MarketScreener. Press Releases Arrowhead Pharmaceuticals, Inc. Biotechnology & Medical Research All financial news and data tailored to…
Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target
Arrowhead Pharmaceuticals has an average rating of buy and mean price target of $111.20, according to analysts polled by FactSet. ... Biotechnology & Medical Research Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com10
-
news.alphastreet.com2
-
tradingview.com2
-
businesswire.com1
-
ir.arrowheadpharma.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.